Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Alto Neuroscience Inc
ANRO
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$24.41
N/A
Últ. Act.: Oct 21, 6:39 AM
$24.41
N/A
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Alto Neuroscience Financials
Alto Neuroscience (ANRO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Alto Neuroscience Q2 EPS $(0.65) Beats $(0.73) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.73) by 10.96 percent. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Alto Neuroscience Q1 EPS $(0.80) Misses $(0.54) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.54) by 48.15 percent. This is a 42.86 percent decrease over losses of $(0.56) per share from
Benzinga Newsdesk
Earnings Scheduled For March 16, 2026
Benzinga Insights
PRO
Alto Neuroscience Q4 EPS $(0.45) Beats $(0.55) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.55) by 18.77 percent. This is a 19.64 percent increase over losses of $(0.56) per share from
Benzinga Newsdesk
PRO
Alto Neuroscience Q3 EPS $(0.52) Beats $(0.67) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.67) by 22.04 percent. This is a 16.13 percent increase over losses of $(0.62) per share from
Benzinga Newsdesk
PRO
Alto Neuroscience Q2 EPS $(0.65) Misses $(0.61) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.61) by 7.08 percent. This is a 8.33 percent decrease over losses of $(0.60) per share from
Benzinga Newsdesk
